Aetna · Clinical coverage policy

Aetna Noninvasive Positive Pressure Ventilation (CPAP/BiPAP) coverage criteria

Aetna CPB 0452 covers noninvasive positive pressure ventilation (bilevel PAP/CPAP), ventilators with noninvasive interfaces, multi-function home ventilators, and related accessories (humidifiers) as DME for specific conditions — restrictive thoracic disorders, severe COPD, central/complex sleep apnea, hypoventilation syndrome, OSA (when CPAP has failed or is not tolerated), tracheomalacia, and postoperative hypoxemic respiratory failure — each gated by documented objective criteria such as ABG PaCO2 thresholds, sleep oximetry desaturation ≤88%, spirometry, and symptoms of sleep-associated hypoventilation. Continued coverage beyond 3 months requires documented compliant use (average 4 hours per 24-hour period) and benefit; a backup-rate feature for primary OSA and several other indications/devices are experimental/investigational or not covered.

Policy CPB 0452 · Effective · Verify against the current Aetna policy before submitting — view source policy.

Payer

Aetna

Policy

CPB 0452

Prior auth

Confirm

Effective

January 1, 2026

This page reflects the coverage criteria captured from Aetna policy CPB 0452 and may not include every criterion, exception, or code — verify the complete bulletin before submitting.

What this means for the claim

The covered path, the next step to get it approved, and the specific way it denies — built only from this policy.

When does Aetna cover Noninvasive Positive Pressure Ventilation (CPAP/BiPAP) (CPT 94002), and what gets it denied?

Path
Aetna CPB 0452 covers noninvasive positive pressure ventilation (bilevel PAP/CPAP), ventilators with noninvasive interfaces, multi-function home ventilators, and related accessories (humidifiers) as DME for specific conditions — restrictive thoracic disorders, severe COPD, central/complex sleep apnea, hypoventilation syndrome, OSA (when CPAP has failed or is not tolerated), tracheomalacia, and postoperative hypoxemic respiratory failure — each gated by documented objective criteria such as ABG PaCO2 thresholds, sleep oximetry desaturation ≤88%, spirometry, and symptoms of sleep-associated hypoventilation. Continued coverage beyond 3 months requires documented compliant use (average 4 hours per 24-hour period) and benefit; a backup-rate feature for primary OSA and several other indications/devices are experimental/investigational or not covered. Coverage criteria include: NPPV with bilevel PAP devices (or bilevel PAP with backup rate feature) is covered as DME for members meeting condition-specific criteria below.; Restrictive thoracic disorders — bilevel PAP medically necessary when ALL of: (1) COPD does not contribute significantly to the member's pulmonary limitation; AND (2) member has a progressive neuromuscular disease (e.g., ALS) OR severe thoracic cage abnormality (e.g., post-thoracoplasty for tuberculosis); AND (3) member exhibits symptoms of sleep-associated hypoventilation (daytime hypersomnolence, excessive fatigue, dyspnea, morning headache, or cognitive dysfunction); AND (4) clinically significant hypoxemia evidenced by ANY of: ABG PaCO2 ≥45 mm Hg (awake, breathing usual FIO2) OR sleep oximetry O2 saturation ≤88% for ≥5 minutes of nocturnal recording (minimum 2 hours, usual FIO2) OR — for progressive neuromuscular disease only — maximal inspiratory pressures <60 cm H2O OR forced vital capacity (FVC) <50% predicted.; Severe COPD — bilevel PAP WITHOUT backup rate medically necessary when ALL of: (1) member exhibits symptoms of sleep-associated hypoventilation (daytime hypersomnolence, excessive fatigue, dyspnea, morning headache, or cognitive dysfunction); AND (2) ABG PaCO2 ≥52 mm Hg; AND (3) sleep oximetry O2 saturation ≤88% for ≥5 cumulative minutes of nocturnal recording (minimum 2 hours), done while breathing oxygen at 2 LPM or the member's prescribed FIO2, whichever is higher; AND (4) prior to initiating therapy, OSA (and treatment with CPAP) has been considered and ruled out — formal sleep testing NOT required if the medical record sufficiently demonstrates the member does not suffer from some form of sleep apnea (OSA, CSA and/or CompSA) as the predominant cause of awake hypercapnia or nocturnal arterial oxygen desaturation.; Severe COPD — bilevel PAP WITH backup rate medically necessary in EITHER scenario. Scenario 1 (escalation after initial bilevel PAP trial), meet ALL of: (a) ABG PaCO2 (awake, prescribed FIO2) worsens ≥7 mm Hg compared to the original PaCO2 ≥52 result; AND (b) facility-based PSG demonstrates O2 saturation ≤88% for ≥5 cumulative minutes of nocturnal recording (minimum 2 hours) while using a bilevel PAP device without backup rate, not caused by obstructive upper airway events — i.e., AHI <5. Scenario 2 (after ≥two months / 60 days of compliant use, averaging 4 hours per 24-hour period, of bilevel PAP without backup rate), meet ALL of: (a) ABG PaCO2 (awake, prescribed FIO2) still remains ≥52 mm Hg; AND (b) sleep oximetry while breathing with the bilevel PAP device without backup rate demonstrates O2 saturation ≤88% for ≥5 cumulative minutes of nocturnal recording (minimum 2 hours), done while breathing oxygen at 2 LPM or prescribed FIO2 (whichever is higher).; Central sleep apnea (CSA) or complex sleep apnea (CompSA) — bilevel PAP (with or without backup rate) medically necessary when, prior to initiating therapy, a complete inpatient, attended polysomnogram documents BOTH of: (1) diagnosis of CSA or CompSA; AND (2) significant improvement of the sleep-associated hypoventilation with use of a bilevel PAP device (with or without backup rate) on the settings that will be prescribed for initial home use, while breathing the member's prescribed FIO2.; Hypoventilation syndrome — bilevel PAP device WITHOUT backup rate medically necessary when criteria i AND ii PLUS (iii OR iv) are met: (i) initial ABG PaCO2 (awake, prescribed FIO2) ≥45 mm Hg; AND (ii) spirometry shows FEV1/FVC ≥70%; AND (iii) ABG PaCO2 done during sleep or immediately upon awakening (prescribed FIO2) shows PaCO2 worsened ≥7 mm Hg compared to the original result; OR (iv) facility-based PSG or home sleep test (HST) demonstrates O2 saturation ≤88% for ≥5 minutes of nocturnal recording (minimum 2 hours) not caused by obstructive upper airway events — i.e., AHI <5.; Hypoventilation syndrome — bilevel PAP device WITH backup rate medically necessary when criteria i AND ii PLUS (iii OR iv) are met: (i) a medically necessary bilevel PAP device without backup rate is being used; AND (ii) spirometry shows FEV1/FVC ≥70%; AND (iii) ABG PaCO2 (awake, prescribed FIO2) shows PaCO2 worsens ≥7 mm Hg compared to the ABG result performed to qualify the member for the bilevel PAP device without backup rate; OR (iv) facility-based PSG or HST demonstrates O2 saturation ≤88% for ≥5 minutes of nocturnal recording (minimum 2 hours) not caused by obstructive upper airway events — i.e., AHI <5 — while using a bilevel device without backup rate.; Obstructive sleep apnea (OSA) — bilevel PAP device WITHOUT backup rate medically necessary when BOTH of: (1) member meets the criteria for CPAP set forth in CPB 0004 (Obstructive Sleep Apnea in Adults) or CPB 0752 (Obstructive Sleep Apnea in Children); AND (2) CPAP has been tried and proven ineffective or is not tolerated. (Note: a backup rate feature for the primary diagnosis of OSA is experimental/investigational/unproven — see exclusions.); Tracheomalacia — continuous positive airway pressure (CPAP) is considered medically necessary for the treatment of tracheomalacia.; Respiratory failure following surgery — NPPV is considered medically necessary for postoperative hypoxemic respiratory failure that is refractory to or not suitable for oxygen.; Continued coverage beyond the first 3 months — members should be re-evaluated after 2 to 3 months; for continued medical necessity beyond 3 months the medical records must document that the member has been compliantly using the device (an average of 4 hours per 24-hour period) and that the member is benefiting from its use.; Humidifiers — either a heated or non-heated humidifier is considered medically necessary for use with NPPV.; Ventilators with noninvasive interfaces — considered medically necessary for severe neuromuscular diseases, thoracic restrictive diseases, and chronic respiratory failure consequent to COPD where interruption or failure of respiratory support would lead to death; Aetna follows CMS policy on ventilators with noninvasive interfaces. (The bilevel PAP conditions above are not life-threatening conditions requiring continuous support, so any type of ventilator is NOT medically necessary for those bilevel PAP indications even if the ventilator can operate in a bilevel PAP mode.); Multi-function home ventilator (e.g., VOCSN, VOCSN VC, VOCSN VC Pro [Ventec Life Systems, Inc.], FDA-approved) — medically necessary when BOTH of: (1) member has a documented diagnosis of a neuromuscular disease, thoracic restrictive disease, or chronic respiratory failure consequent to COPD requiring positive pressure mechanical ventilation where interruption or failure of respiratory support would lead to death; AND (2) documentation supports the need for more than one additional function (i.e., oxygen concentrator, cough stimulator, suction pump, nebulization).; Second respiratory assist device (invasive or non-invasive) — medically necessary when required to serve a different purpose as determined by the member's medical needs. Examples (not all-inclusive): (1) member requires one type of respiratory assist device (e.g., a negative pressure ventilator with a chest shell) for part of the day and a different type (e.g., positive pressure respiratory assist device with a nasal mask) for the rest of the day; (2) member confined to a wheelchair requires a respiratory assist device mounted on the wheelchair for daytime use and another device of the same type for use while in bed, where without both the member may be prone to medical complications, unable to achieve appropriate outcomes, or unable to use the equipment effectively.. Applies to 22 codes: 94002, 94003, 94660, E0470, E0471, E0601, A7027, A7028, A7029, A7030, A7031, A7032, A7033, A7034, A7035, A7036, A7037, A7038, A7039, A7044, A7045, A7046.
Action
Confirm prior-authorization status with Aetna before scheduling — it is code- and plan-specific, and this policy is not an exact authorization source. Documentation: Restrictive thoracic disorders: evidence that COPD does not significantly contribute to pulmonary limitation; documentation of progressive neuromuscular disease or severe thoracic cage abnormality; documentation of sleep-associated hypoventilation symptoms; and ABG (awake, usual FIO2) OR sleep oximetry results OR (for neuromuscular disease) maximal inspiratory pressure / FVC measurements.; Severe COPD: documentation of sleep-associated hypoventilation symptoms; ABG showing PaCO2 ≥52 mm Hg; sleep oximetry (≤88% saturation for ≥5 cumulative minutes, minimum 2 hours, on 2 LPM oxygen or prescribed FIO2); and sufficient information in the medical record demonstrating the member does not suffer from a form of sleep apnea (OSA, CSA and/or CompSA) as the predominant cause of awake hypercapnia or nocturnal desaturation (formal sleep testing not required if so documented).; CSA/CompSA: a complete inpatient, attended polysomnogram documenting the CSA or CompSA diagnosis AND demonstrating significant improvement of sleep-associated hypoventilation with the bilevel PAP device (with or without backup rate) on the settings to be prescribed for initial home use, while breathing the member's prescribed FIO2.; Hypoventilation syndrome: ABG PaCO2 measurement (awake, prescribed FIO2); spirometry (FEV1/FVC); and an additional ABG during sleep or immediately upon waking OR PSG/HST results.; OSA: documentation that the member meets CPAP criteria per CPB 0004 or CPB 0752, and documentation that CPAP has been tried and proven ineffective or is not tolerated.; Continued coverage beyond 3 months: medical records documenting compliant device use (an average of 4 hours per 24-hour period) and that the member is benefiting from its use.; Multi-function home ventilator: documented diagnosis of neuromuscular disease, thoracic restrictive disease, or chronic respiratory failure consequent to COPD, and documentation supporting the need for more than one additional function beyond ventilation.
Trap
Policy exclusions and limitations: NPPV for all other indications not listed in the medically necessary section is not covered/considered not medically necessary, including (not an all-inclusive list): acute lung injury; as an alternative to endotracheal intubation following esophagectomy; asthma; bronchiolitis in infants and children; pneumonia; prevention of complications after pulmonary resection for lung cancer.; A backup rate feature for a bilevel PAP device is of no proven value for the primary diagnosis of OSA and is therefore considered experimental, investigational, or unproven.; Single-breath tests for determining airway closure volume — single-breath nitrogen testing (also known as single-breath oxygen testing) is considered experimental, investigational, or unproven because its value in the management of persons with pulmonary disorders/diseases has not been established; single-breath tests using other tracer gases such as xenon, argon, or helium are also experimental, investigational, or unproven due to insufficient evidence in the peer-reviewed literature.; Exsufflation belt (intermittent abdominal daytime pressure ventilator) is considered experimental, investigational, or unproven for pulmonary restrictive or pulmonary obstructive breathing.; A liner used in conjunction with a PAP mask is considered a comfort/convenience item (not covered DME).; Electrical generators to power respirators, bilevel PAP devices, etc. do not meet Aetna's definition of DME because they are not primarily medical in nature and are of use in the absence of illness or injury (not covered). Claims may be denied when the requested service falls under these.

Source: Aetna CPB 0452 — Noninvasive Positive Pressure Ventilation (CPAP/BiPAP)

Coverage criteria

  • NPPV with bilevel PAP devices (or bilevel PAP with backup rate feature) is covered as DME for members meeting condition-specific criteria below.
  • Restrictive thoracic disorders — bilevel PAP medically necessary when ALL of: (1) COPD does not contribute significantly to the member's pulmonary limitation; AND (2) member has a progressive neuromuscular disease (e.g., ALS) OR severe thoracic cage abnormality (e.g., post-thoracoplasty for tuberculosis); AND (3) member exhibits symptoms of sleep-associated hypoventilation (daytime hypersomnolence, excessive fatigue, dyspnea, morning headache, or cognitive dysfunction); AND (4) clinically significant hypoxemia evidenced by ANY of: ABG PaCO2 ≥45 mm Hg (awake, breathing usual FIO2) OR sleep oximetry O2 saturation ≤88% for ≥5 minutes of nocturnal recording (minimum 2 hours, usual FIO2) OR — for progressive neuromuscular disease only — maximal inspiratory pressures <60 cm H2O OR forced vital capacity (FVC) <50% predicted.
  • Severe COPD — bilevel PAP WITHOUT backup rate medically necessary when ALL of: (1) member exhibits symptoms of sleep-associated hypoventilation (daytime hypersomnolence, excessive fatigue, dyspnea, morning headache, or cognitive dysfunction); AND (2) ABG PaCO2 ≥52 mm Hg; AND (3) sleep oximetry O2 saturation ≤88% for ≥5 cumulative minutes of nocturnal recording (minimum 2 hours), done while breathing oxygen at 2 LPM or the member's prescribed FIO2, whichever is higher; AND (4) prior to initiating therapy, OSA (and treatment with CPAP) has been considered and ruled out — formal sleep testing NOT required if the medical record sufficiently demonstrates the member does not suffer from some form of sleep apnea (OSA, CSA and/or CompSA) as the predominant cause of awake hypercapnia or nocturnal arterial oxygen desaturation.
  • Severe COPD — bilevel PAP WITH backup rate medically necessary in EITHER scenario. Scenario 1 (escalation after initial bilevel PAP trial), meet ALL of: (a) ABG PaCO2 (awake, prescribed FIO2) worsens ≥7 mm Hg compared to the original PaCO2 ≥52 result; AND (b) facility-based PSG demonstrates O2 saturation ≤88% for ≥5 cumulative minutes of nocturnal recording (minimum 2 hours) while using a bilevel PAP device without backup rate, not caused by obstructive upper airway events — i.e., AHI <5. Scenario 2 (after ≥two months / 60 days of compliant use, averaging 4 hours per 24-hour period, of bilevel PAP without backup rate), meet ALL of: (a) ABG PaCO2 (awake, prescribed FIO2) still remains ≥52 mm Hg; AND (b) sleep oximetry while breathing with the bilevel PAP device without backup rate demonstrates O2 saturation ≤88% for ≥5 cumulative minutes of nocturnal recording (minimum 2 hours), done while breathing oxygen at 2 LPM or prescribed FIO2 (whichever is higher).
  • Central sleep apnea (CSA) or complex sleep apnea (CompSA) — bilevel PAP (with or without backup rate) medically necessary when, prior to initiating therapy, a complete inpatient, attended polysomnogram documents BOTH of: (1) diagnosis of CSA or CompSA; AND (2) significant improvement of the sleep-associated hypoventilation with use of a bilevel PAP device (with or without backup rate) on the settings that will be prescribed for initial home use, while breathing the member's prescribed FIO2.
  • Hypoventilation syndrome — bilevel PAP device WITHOUT backup rate medically necessary when criteria i AND ii PLUS (iii OR iv) are met: (i) initial ABG PaCO2 (awake, prescribed FIO2) ≥45 mm Hg; AND (ii) spirometry shows FEV1/FVC ≥70%; AND (iii) ABG PaCO2 done during sleep or immediately upon awakening (prescribed FIO2) shows PaCO2 worsened ≥7 mm Hg compared to the original result; OR (iv) facility-based PSG or home sleep test (HST) demonstrates O2 saturation ≤88% for ≥5 minutes of nocturnal recording (minimum 2 hours) not caused by obstructive upper airway events — i.e., AHI <5.
  • Hypoventilation syndrome — bilevel PAP device WITH backup rate medically necessary when criteria i AND ii PLUS (iii OR iv) are met: (i) a medically necessary bilevel PAP device without backup rate is being used; AND (ii) spirometry shows FEV1/FVC ≥70%; AND (iii) ABG PaCO2 (awake, prescribed FIO2) shows PaCO2 worsens ≥7 mm Hg compared to the ABG result performed to qualify the member for the bilevel PAP device without backup rate; OR (iv) facility-based PSG or HST demonstrates O2 saturation ≤88% for ≥5 minutes of nocturnal recording (minimum 2 hours) not caused by obstructive upper airway events — i.e., AHI <5 — while using a bilevel device without backup rate.
  • Obstructive sleep apnea (OSA) — bilevel PAP device WITHOUT backup rate medically necessary when BOTH of: (1) member meets the criteria for CPAP set forth in CPB 0004 (Obstructive Sleep Apnea in Adults) or CPB 0752 (Obstructive Sleep Apnea in Children); AND (2) CPAP has been tried and proven ineffective or is not tolerated. (Note: a backup rate feature for the primary diagnosis of OSA is experimental/investigational/unproven — see exclusions.)
  • Tracheomalacia — continuous positive airway pressure (CPAP) is considered medically necessary for the treatment of tracheomalacia.
  • Respiratory failure following surgery — NPPV is considered medically necessary for postoperative hypoxemic respiratory failure that is refractory to or not suitable for oxygen.
  • Continued coverage beyond the first 3 months — members should be re-evaluated after 2 to 3 months; for continued medical necessity beyond 3 months the medical records must document that the member has been compliantly using the device (an average of 4 hours per 24-hour period) and that the member is benefiting from its use.
  • Humidifiers — either a heated or non-heated humidifier is considered medically necessary for use with NPPV.
  • Ventilators with noninvasive interfaces — considered medically necessary for severe neuromuscular diseases, thoracic restrictive diseases, and chronic respiratory failure consequent to COPD where interruption or failure of respiratory support would lead to death; Aetna follows CMS policy on ventilators with noninvasive interfaces. (The bilevel PAP conditions above are not life-threatening conditions requiring continuous support, so any type of ventilator is NOT medically necessary for those bilevel PAP indications even if the ventilator can operate in a bilevel PAP mode.)
  • Multi-function home ventilator (e.g., VOCSN, VOCSN VC, VOCSN VC Pro [Ventec Life Systems, Inc.], FDA-approved) — medically necessary when BOTH of: (1) member has a documented diagnosis of a neuromuscular disease, thoracic restrictive disease, or chronic respiratory failure consequent to COPD requiring positive pressure mechanical ventilation where interruption or failure of respiratory support would lead to death; AND (2) documentation supports the need for more than one additional function (i.e., oxygen concentrator, cough stimulator, suction pump, nebulization).
  • Second respiratory assist device (invasive or non-invasive) — medically necessary when required to serve a different purpose as determined by the member's medical needs. Examples (not all-inclusive): (1) member requires one type of respiratory assist device (e.g., a negative pressure ventilator with a chest shell) for part of the day and a different type (e.g., positive pressure respiratory assist device with a nasal mask) for the rest of the day; (2) member confined to a wheelchair requires a respiratory assist device mounted on the wheelchair for daytime use and another device of the same type for use while in bed, where without both the member may be prone to medical complications, unable to achieve appropriate outcomes, or unable to use the equipment effectively.

Covered codes

Codes listed in this Aetna policy. Check each one's prior-authorization verdict and Medicare rate:

Documentation required

  • Restrictive thoracic disorders: evidence that COPD does not significantly contribute to pulmonary limitation; documentation of progressive neuromuscular disease or severe thoracic cage abnormality; documentation of sleep-associated hypoventilation symptoms; and ABG (awake, usual FIO2) OR sleep oximetry results OR (for neuromuscular disease) maximal inspiratory pressure / FVC measurements.
  • Severe COPD: documentation of sleep-associated hypoventilation symptoms; ABG showing PaCO2 ≥52 mm Hg; sleep oximetry (≤88% saturation for ≥5 cumulative minutes, minimum 2 hours, on 2 LPM oxygen or prescribed FIO2); and sufficient information in the medical record demonstrating the member does not suffer from a form of sleep apnea (OSA, CSA and/or CompSA) as the predominant cause of awake hypercapnia or nocturnal desaturation (formal sleep testing not required if so documented).
  • CSA/CompSA: a complete inpatient, attended polysomnogram documenting the CSA or CompSA diagnosis AND demonstrating significant improvement of sleep-associated hypoventilation with the bilevel PAP device (with or without backup rate) on the settings to be prescribed for initial home use, while breathing the member's prescribed FIO2.
  • Hypoventilation syndrome: ABG PaCO2 measurement (awake, prescribed FIO2); spirometry (FEV1/FVC); and an additional ABG during sleep or immediately upon waking OR PSG/HST results.
  • OSA: documentation that the member meets CPAP criteria per CPB 0004 or CPB 0752, and documentation that CPAP has been tried and proven ineffective or is not tolerated.
  • Continued coverage beyond 3 months: medical records documenting compliant device use (an average of 4 hours per 24-hour period) and that the member is benefiting from its use.
  • Multi-function home ventilator: documented diagnosis of neuromuscular disease, thoracic restrictive disease, or chronic respiratory failure consequent to COPD, and documentation supporting the need for more than one additional function beyond ventilation.

Frequently asked questions

When does Aetna cover Noninvasive Positive Pressure Ventilation (CPAP/BiPAP) (CPT 94002), and what gets it denied?
Aetna CPB 0452 covers noninvasive positive pressure ventilation (bilevel PAP/CPAP), ventilators with noninvasive interfaces, multi-function home ventilators, and related accessories (humidifiers) as DME for specific conditions — restrictive thoracic disorders, severe COPD, central/complex sleep apnea, hypoventilation syndrome, OSA (when CPAP has failed or is not tolerated), tracheomalacia, and postoperative hypoxemic respiratory failure — each gated by documented objective criteria such as ABG PaCO2 thresholds, sleep oximetry desaturation ≤88%, spirometry, and symptoms of sleep-associated hypoventilation. Continued coverage beyond 3 months requires documented compliant use (average 4 hours per 24-hour period) and benefit; a backup-rate feature for primary OSA and several other indications/devices are experimental/investigational or not covered. Coverage criteria include: NPPV with bilevel PAP devices (or bilevel PAP with backup rate feature) is covered as DME for members meeting condition-specific criteria below.; Restrictive thoracic disorders — bilevel PAP medically necessary when ALL of: (1) COPD does not contribute significantly to the member's pulmonary limitation; AND (2) member has a progressive neuromuscular disease (e.g., ALS) OR severe thoracic cage abnormality (e.g., post-thoracoplasty for tuberculosis); AND (3) member exhibits symptoms of sleep-associated hypoventilation (daytime hypersomnolence, excessive fatigue, dyspnea, morning headache, or cognitive dysfunction); AND (4) clinically significant hypoxemia evidenced by ANY of: ABG PaCO2 ≥45 mm Hg (awake, breathing usual FIO2) OR sleep oximetry O2 saturation ≤88% for ≥5 minutes of nocturnal recording (minimum 2 hours, usual FIO2) OR — for progressive neuromuscular disease only — maximal inspiratory pressures <60 cm H2O OR forced vital capacity (FVC) <50% predicted.; Severe COPD — bilevel PAP WITHOUT backup rate medically necessary when ALL of: (1) member exhibits symptoms of sleep-associated hypoventilation (daytime hypersomnolence, excessive fatigue, dyspnea, morning headache, or cognitive dysfunction); AND (2) ABG PaCO2 ≥52 mm Hg; AND (3) sleep oximetry O2 saturation ≤88% for ≥5 cumulative minutes of nocturnal recording (minimum 2 hours), done while breathing oxygen at 2 LPM or the member's prescribed FIO2, whichever is higher; AND (4) prior to initiating therapy, OSA (and treatment with CPAP) has been considered and ruled out — formal sleep testing NOT required if the medical record sufficiently demonstrates the member does not suffer from some form of sleep apnea (OSA, CSA and/or CompSA) as the predominant cause of awake hypercapnia or nocturnal arterial oxygen desaturation.; Severe COPD — bilevel PAP WITH backup rate medically necessary in EITHER scenario. Scenario 1 (escalation after initial bilevel PAP trial), meet ALL of: (a) ABG PaCO2 (awake, prescribed FIO2) worsens ≥7 mm Hg compared to the original PaCO2 ≥52 result; AND (b) facility-based PSG demonstrates O2 saturation ≤88% for ≥5 cumulative minutes of nocturnal recording (minimum 2 hours) while using a bilevel PAP device without backup rate, not caused by obstructive upper airway events — i.e., AHI <5. Scenario 2 (after ≥two months / 60 days of compliant use, averaging 4 hours per 24-hour period, of bilevel PAP without backup rate), meet ALL of: (a) ABG PaCO2 (awake, prescribed FIO2) still remains ≥52 mm Hg; AND (b) sleep oximetry while breathing with the bilevel PAP device without backup rate demonstrates O2 saturation ≤88% for ≥5 cumulative minutes of nocturnal recording (minimum 2 hours), done while breathing oxygen at 2 LPM or prescribed FIO2 (whichever is higher).; Central sleep apnea (CSA) or complex sleep apnea (CompSA) — bilevel PAP (with or without backup rate) medically necessary when, prior to initiating therapy, a complete inpatient, attended polysomnogram documents BOTH of: (1) diagnosis of CSA or CompSA; AND (2) significant improvement of the sleep-associated hypoventilation with use of a bilevel PAP device (with or without backup rate) on the settings that will be prescribed for initial home use, while breathing the member's prescribed FIO2.; Hypoventilation syndrome — bilevel PAP device WITHOUT backup rate medically necessary when criteria i AND ii PLUS (iii OR iv) are met: (i) initial ABG PaCO2 (awake, prescribed FIO2) ≥45 mm Hg; AND (ii) spirometry shows FEV1/FVC ≥70%; AND (iii) ABG PaCO2 done during sleep or immediately upon awakening (prescribed FIO2) shows PaCO2 worsened ≥7 mm Hg compared to the original result; OR (iv) facility-based PSG or home sleep test (HST) demonstrates O2 saturation ≤88% for ≥5 minutes of nocturnal recording (minimum 2 hours) not caused by obstructive upper airway events — i.e., AHI <5.; Hypoventilation syndrome — bilevel PAP device WITH backup rate medically necessary when criteria i AND ii PLUS (iii OR iv) are met: (i) a medically necessary bilevel PAP device without backup rate is being used; AND (ii) spirometry shows FEV1/FVC ≥70%; AND (iii) ABG PaCO2 (awake, prescribed FIO2) shows PaCO2 worsens ≥7 mm Hg compared to the ABG result performed to qualify the member for the bilevel PAP device without backup rate; OR (iv) facility-based PSG or HST demonstrates O2 saturation ≤88% for ≥5 minutes of nocturnal recording (minimum 2 hours) not caused by obstructive upper airway events — i.e., AHI <5 — while using a bilevel device without backup rate.; Obstructive sleep apnea (OSA) — bilevel PAP device WITHOUT backup rate medically necessary when BOTH of: (1) member meets the criteria for CPAP set forth in CPB 0004 (Obstructive Sleep Apnea in Adults) or CPB 0752 (Obstructive Sleep Apnea in Children); AND (2) CPAP has been tried and proven ineffective or is not tolerated. (Note: a backup rate feature for the primary diagnosis of OSA is experimental/investigational/unproven — see exclusions.); Tracheomalacia — continuous positive airway pressure (CPAP) is considered medically necessary for the treatment of tracheomalacia.; Respiratory failure following surgery — NPPV is considered medically necessary for postoperative hypoxemic respiratory failure that is refractory to or not suitable for oxygen.; Continued coverage beyond the first 3 months — members should be re-evaluated after 2 to 3 months; for continued medical necessity beyond 3 months the medical records must document that the member has been compliantly using the device (an average of 4 hours per 24-hour period) and that the member is benefiting from its use.; Humidifiers — either a heated or non-heated humidifier is considered medically necessary for use with NPPV.; Ventilators with noninvasive interfaces — considered medically necessary for severe neuromuscular diseases, thoracic restrictive diseases, and chronic respiratory failure consequent to COPD where interruption or failure of respiratory support would lead to death; Aetna follows CMS policy on ventilators with noninvasive interfaces. (The bilevel PAP conditions above are not life-threatening conditions requiring continuous support, so any type of ventilator is NOT medically necessary for those bilevel PAP indications even if the ventilator can operate in a bilevel PAP mode.); Multi-function home ventilator (e.g., VOCSN, VOCSN VC, VOCSN VC Pro [Ventec Life Systems, Inc.], FDA-approved) — medically necessary when BOTH of: (1) member has a documented diagnosis of a neuromuscular disease, thoracic restrictive disease, or chronic respiratory failure consequent to COPD requiring positive pressure mechanical ventilation where interruption or failure of respiratory support would lead to death; AND (2) documentation supports the need for more than one additional function (i.e., oxygen concentrator, cough stimulator, suction pump, nebulization).; Second respiratory assist device (invasive or non-invasive) — medically necessary when required to serve a different purpose as determined by the member's medical needs. Examples (not all-inclusive): (1) member requires one type of respiratory assist device (e.g., a negative pressure ventilator with a chest shell) for part of the day and a different type (e.g., positive pressure respiratory assist device with a nasal mask) for the rest of the day; (2) member confined to a wheelchair requires a respiratory assist device mounted on the wheelchair for daytime use and another device of the same type for use while in bed, where without both the member may be prone to medical complications, unable to achieve appropriate outcomes, or unable to use the equipment effectively.. Applies to 22 codes: 94002, 94003, 94660, E0470, E0471, E0601, A7027, A7028, A7029, A7030, A7031, A7032, A7033, A7034, A7035, A7036, A7037, A7038, A7039, A7044, A7045, A7046. Confirm prior-authorization status with Aetna before scheduling — it is code- and plan-specific, and this policy is not an exact authorization source. Documentation: Restrictive thoracic disorders: evidence that COPD does not significantly contribute to pulmonary limitation; documentation of progressive neuromuscular disease or severe thoracic cage abnormality; documentation of sleep-associated hypoventilation symptoms; and ABG (awake, usual FIO2) OR sleep oximetry results OR (for neuromuscular disease) maximal inspiratory pressure / FVC measurements.; Severe COPD: documentation of sleep-associated hypoventilation symptoms; ABG showing PaCO2 ≥52 mm Hg; sleep oximetry (≤88% saturation for ≥5 cumulative minutes, minimum 2 hours, on 2 LPM oxygen or prescribed FIO2); and sufficient information in the medical record demonstrating the member does not suffer from a form of sleep apnea (OSA, CSA and/or CompSA) as the predominant cause of awake hypercapnia or nocturnal desaturation (formal sleep testing not required if so documented).; CSA/CompSA: a complete inpatient, attended polysomnogram documenting the CSA or CompSA diagnosis AND demonstrating significant improvement of sleep-associated hypoventilation with the bilevel PAP device (with or without backup rate) on the settings to be prescribed for initial home use, while breathing the member's prescribed FIO2.; Hypoventilation syndrome: ABG PaCO2 measurement (awake, prescribed FIO2); spirometry (FEV1/FVC); and an additional ABG during sleep or immediately upon waking OR PSG/HST results.; OSA: documentation that the member meets CPAP criteria per CPB 0004 or CPB 0752, and documentation that CPAP has been tried and proven ineffective or is not tolerated.; Continued coverage beyond 3 months: medical records documenting compliant device use (an average of 4 hours per 24-hour period) and that the member is benefiting from its use.; Multi-function home ventilator: documented diagnosis of neuromuscular disease, thoracic restrictive disease, or chronic respiratory failure consequent to COPD, and documentation supporting the need for more than one additional function beyond ventilation. Policy exclusions and limitations: NPPV for all other indications not listed in the medically necessary section is not covered/considered not medically necessary, including (not an all-inclusive list): acute lung injury; as an alternative to endotracheal intubation following esophagectomy; asthma; bronchiolitis in infants and children; pneumonia; prevention of complications after pulmonary resection for lung cancer.; A backup rate feature for a bilevel PAP device is of no proven value for the primary diagnosis of OSA and is therefore considered experimental, investigational, or unproven.; Single-breath tests for determining airway closure volume — single-breath nitrogen testing (also known as single-breath oxygen testing) is considered experimental, investigational, or unproven because its value in the management of persons with pulmonary disorders/diseases has not been established; single-breath tests using other tracer gases such as xenon, argon, or helium are also experimental, investigational, or unproven due to insufficient evidence in the peer-reviewed literature.; Exsufflation belt (intermittent abdominal daytime pressure ventilator) is considered experimental, investigational, or unproven for pulmonary restrictive or pulmonary obstructive breathing.; A liner used in conjunction with a PAP mask is considered a comfort/convenience item (not covered DME).; Electrical generators to power respirators, bilevel PAP devices, etc. do not meet Aetna's definition of DME because they are not primarily medical in nature and are of use in the absence of illness or injury (not covered). Claims may be denied when the requested service falls under these.
Does Aetna require prior authorization for Noninvasive Positive Pressure Ventilation (CPAP/BiPAP)?
Confirm prior-authorization status with Aetna before scheduling — it is code- and plan-specific, and this policy is not an exact authorization source. Documentation: Restrictive thoracic disorders: evidence that COPD does not significantly contribute to pulmonary limitation; documentation of progressive neuromuscular disease or severe thoracic cage abnormality; documentation of sleep-associated hypoventilation symptoms; and ABG (awake, usual FIO2) OR sleep oximetry results OR (for neuromuscular disease) maximal inspiratory pressure / FVC measurements.; Severe COPD: documentation of sleep-associated hypoventilation symptoms; ABG showing PaCO2 ≥52 mm Hg; sleep oximetry (≤88% saturation for ≥5 cumulative minutes, minimum 2 hours, on 2 LPM oxygen or prescribed FIO2); and sufficient information in the medical record demonstrating the member does not suffer from a form of sleep apnea (OSA, CSA and/or CompSA) as the predominant cause of awake hypercapnia or nocturnal desaturation (formal sleep testing not required if so documented).; CSA/CompSA: a complete inpatient, attended polysomnogram documenting the CSA or CompSA diagnosis AND demonstrating significant improvement of sleep-associated hypoventilation with the bilevel PAP device (with or without backup rate) on the settings to be prescribed for initial home use, while breathing the member's prescribed FIO2.; Hypoventilation syndrome: ABG PaCO2 measurement (awake, prescribed FIO2); spirometry (FEV1/FVC); and an additional ABG during sleep or immediately upon waking OR PSG/HST results.; OSA: documentation that the member meets CPAP criteria per CPB 0004 or CPB 0752, and documentation that CPAP has been tried and proven ineffective or is not tolerated.; Continued coverage beyond 3 months: medical records documenting compliant device use (an average of 4 hours per 24-hour period) and that the member is benefiting from its use.; Multi-function home ventilator: documented diagnosis of neuromuscular disease, thoracic restrictive disease, or chronic respiratory failure consequent to COPD, and documentation supporting the need for more than one additional function beyond ventilation.
What does Aetna exclude for Noninvasive Positive Pressure Ventilation (CPAP/BiPAP)?
Policy exclusions and limitations: NPPV for all other indications not listed in the medically necessary section is not covered/considered not medically necessary, including (not an all-inclusive list): acute lung injury; as an alternative to endotracheal intubation following esophagectomy; asthma; bronchiolitis in infants and children; pneumonia; prevention of complications after pulmonary resection for lung cancer.; A backup rate feature for a bilevel PAP device is of no proven value for the primary diagnosis of OSA and is therefore considered experimental, investigational, or unproven.; Single-breath tests for determining airway closure volume — single-breath nitrogen testing (also known as single-breath oxygen testing) is considered experimental, investigational, or unproven because its value in the management of persons with pulmonary disorders/diseases has not been established; single-breath tests using other tracer gases such as xenon, argon, or helium are also experimental, investigational, or unproven due to insufficient evidence in the peer-reviewed literature.; Exsufflation belt (intermittent abdominal daytime pressure ventilator) is considered experimental, investigational, or unproven for pulmonary restrictive or pulmonary obstructive breathing.; A liner used in conjunction with a PAP mask is considered a comfort/convenience item (not covered DME).; Electrical generators to power respirators, bilevel PAP devices, etc. do not meet Aetna's definition of DME because they are not primarily medical in nature and are of use in the absence of illness or injury (not covered). Claims may be denied when the requested service falls under these.

Source

Aetna CPB 0452 — Noninvasive Positive Pressure Ventilation (CPAP/BiPAP)

Related

Need this Aetna approval drafted?

Ask D3 builds the documentation checklist and a ready-to-send request from this policy's criteria — cited, free, no signup.

Ask D3 Free

Coverage disclaimer

This page summarizes Aetna clinical-coverage criteria extracted from policy CPB 0452 for educational purposes. Coverage policies change and vary by individual plan. Always verify against Aetna's current policy before performing a procedure or submitting a claim. d3rx is not responsible for claim denials or reimbursement issues.